ZYBERNO
Stock Report
Updated Aug 31, 2026

HutchMED (China) LIMITED (HCM)

Healthcare • NASDAQ

$12.38
HUTCHMED (China) Limited is a Chinese oncology biopharmaceutical company headquartered in Hong Kong, focused on discovering and developing innovative medicines for cancer treatment. The company's approved products include Orpathys (savolitinib, for MET-driven NSCLC, partnered with AstraZeneca), fruquintinib (colorectal cancer, partnered with Takeda as Fruzaqla for U.S. approval), and a pipeline of novel targeted therapies.

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
17.0/100
POOR BUSINESS
HutchMED (China) LIMITED (HCM) scores 17/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.08x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-7.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

HutchMED (China) LIMITED (HCM) stock report — Zyberno Score 17/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:12.38
Market Cap:$16.98B

Valuation Multiples (2)

P/B Ratio:13.57x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$15.71B

Price Action & Momentum (3)

Momentum Percentile:17 / 100
% of 52-Week High:43.0%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:-2.9%
Fundamental Growth Rate (g):0.2%

Margin Analysis (1)

Ebitda Margin:-5.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.96x
Quick Ratio:4.83x
Cash Ratio:4.33x

Leverage Analysis (3)

Debt To Equity Ttm:0.08x
Debt-to-Equity Ratio:0.08x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-13.67x
Times Interest Earned:-13.67

Capital Structure (4)

Working Capital:1,251,567,000.00
Cash And Cash Equivalents:1,367,275,000.00
Long Term Debt:$68.19M
Net Debt:-$1.27B
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$548.51M
Cost Of Revenue Ttm:$336.35M

Profitability Breakdown (2)

$0.00-$39.16M

Bottom Line Performance (3)

$456.91M
Income Before Tax:-$34.91M
Ebitda Ttm:-27,162,000.00

Operating Expenses (5)

Operating Expenses:88,218,000.00
R And D Expense:33,282,000.00
Sga Expense:10,195,000.00
Income Tax Expense:$1.31M
Interest Expense:2,865,000.00

Expense Ratios (3)

R And D To Revenue Percentage:63.8%
Sga To Revenue Percentage:19.5%
Ebitda Margin:-5.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.75B
Current Assets:$1.57B
Ppe Net:94,623,000.00
Goodwill:3,112,000.00
Intangible Assets:$8.94M

Liability Structure (4)

Total Liabilities:501,835,000.00
Current Liabilities:315,775,000.00
Long Term Debt:$68.19M
Short Term Debt:$24.97M

Equity & Capital (3)

Equity:$1.25B
Retained Earnings:-$378.64M
Common Stock:1,500,000,000.00

Working Capital Items (3)

Accounts Receivable:126,750,000.00
Inventory:41,129,000.00
Accounts Payable:45,533,000.00

Special Items (2)

Contract Liabilities:51,547,000.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$64.66M-$78.81M

Investment Activities (1)

Investing Cash Flow:$33.38M

Financing Activities (3)

Financing Cash Flow:-$346.00K
Dividends Paid Ttm:0.00
Stock Repurchase:346,000.00

Capital Transactions (3)

Common Stock Issuance:254,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:11,998,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:$0.33

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.40
Operating Cash Flow Per Share:-$0.05

Book Value & Capital (2)

Book Value Per Share:$0.91
Cash Per Share:1.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.31x
Working Capital Turnover Ttm:0.44x

Receivables Management (2)

Receivables Turnover Ttm:4.33x
Days Sales Outstanding Ttm:84.34

Inventory Management (2)

Inventory Turnover Ttm:8.18x
Days Inventory Outstanding Ttm:44.63

Payables & Cash Cycle (2)

Days Payable Outstanding:49.41
Cash Conversion Cycle:79.56
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:70.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-2.9%
Fundamental Growth Rate (g):0.2%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:HCM
Company Name:HutchMED (China) LIMITED
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:1.37B
Shares Outstanding Basic:665.47M
Shares Outstanding Diluted:872.89M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 10:01:04 UTC
Data Timestamp:2026-08-31T10:01:04.213099
Scroll to Top